PL EN


Preferences help
enabled [disable] Abstract
Number of results
Journal
2009 | 4 | 4 | 501-505
Article title

Familial multiple myeloma. Two more families

Content
Title variants
Languages of publication
EN
Abstracts
EN
The authors report on two multiple myeloma sibling pairs. In the absence of a known disease-specific marker one can only speculate on an explanation: is it because of inherited errors or is it related to the same environmental exposure, or both? In this study HLA typing and metabolizing enzyme polymorphism studies have been carried out with the aim of finding inherited similarities in the siblings or characteristics that might differ from the average population. Sibling pair 1 shared an HLA haplotype. Sibling pair 2 shared only HLA-B51, DR4, DRw53, DQ3. Sibling 1/1 was GSTT1 / GSTM1 null and GSTP1 Ile105Val; sibling 1/2 was a GSTT1 / GSTM1 heterozygote and GSTP1 Ile105Val; sibling 2/1 and 2/2 were GSTT1 heterozygotes and shared GSTM1 null / GSTP1 Ile105Ile. The siblings had identical light chain or heavy chain secretion, or both. The similarities found in the inherited factors together with the same environmental exposure in the siblings’ first 20 years of life imply that the development of the same disease cannot be a coincidence.
Publisher
Journal
Year
Volume
4
Issue
4
Pages
501-505
Physical description
Dates
published
1 - 12 - 2009
online
3 - 10 - 2009
References
  • [1] Staff I). NIH lymphocyte microcytotoxicity technique. In: Manual of Tissue Typing Technique, Bethesda 1976; 22–24
  • [2] Olerup O, Zetterquist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCRSSP) in two hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantations. Tissue Antigens 1992, 39, 225–232 http://dx.doi.org/10.1111/j.1399-0039.1992.tb01940.x[Crossref]
  • [3] Lin DX, Tang YM, Peng Q, Lu SX, Ambrosone CB, Kadlubar FF. Susceptibility to esophageal cancer and genetic polymorphisms in glutathione S-transferases T1, P1 and M1 and cytochrome P450 2E1. Cancer Epidemiol Biomarkers Prev 1998, 7, 1013–1018
  • [4] Ozawa S, Schoket B, McDaniel LP, Tang YM, Ambrosone CB, Kostic SZ, Vincze I, Kadluber FF. Analyses of bronchial bulky DNA adduct levels and CYP2C9, GSTP1 and NQO1 genotypes in a Hungarian study population with pulmonary diseases. Carcinogenesis. 1999, 20, 991–995 http://dx.doi.org/10.1093/carcin/20.6.991[Crossref]
  • [5] Varkonyi J, Kovalszky I, Nemeth A, Demeter J, Raposa T. Increased risk for cancer in multiple myeloma patients and their first-degree relatives. Haematologia 2001, 31, 45–50 http://dx.doi.org/10.1163/15685590151092698[Crossref]
  • [6] Lynch HT, Sanger WG, Pirucclle S, Quinn-Laguer B, Weisenburger DD. Familial multiple myeloma: A family study and review of the literature. JNCI 2001, 93, 1479–83 http://dx.doi.org/10.1093/jnci/93.19.1479[Crossref]
  • [7] Sobol H, Vey N, Sauvan R, Philip N, Noguchi T, Eisinger F. Re: Familial multiple myeloma: a family study and review of the literature. JNCI 2002, 94, 461–462 [Crossref]
  • [8] Raposa T, Várkonyi J. Leukemogenic risk prediction of the cytostatic treatment. In: Mutation and Environment, Part D. Carcinogenesis. Progr. Clin. Biol. Res. 340: 53–63. Eds.: M.L. Mendelshon and R.J. Albertini. Wiley-Liss Inc., 1990, New York
  • [9] Ortega MM, Nascimento H, Melo M, Teori MT, Costa FF, Lima CSP. Polymorphism of glutathione S-transferase Mu1 (GSTM1) and Theta1 (GSTT1) genes in multiple myeloma. Acta Haematol 2003, 109, 108–109 http://dx.doi.org/10.1159/000068486[Crossref]
  • [10] Várkonyi J, Szakály D, Jánoskúti L, Hosszúfalusi N, Pánczél P, Karádi I, Mikala G, Tordai A, Schoket B. Metabolizing enzyme polymorphism studies in multiple myeloma. Turkish Journal of Haematology 2005; 22(S); Abstr.No.104. XXXth World Congress of the International Society of Hematology September 28-October 2, 2005. Istanbul
  • [11] Lincz LF, Kerridge I, Scorgie FE, Bailey M, Anno A, Spencer A. Xenobiotic gene polymorphisms and susceptibility to multiple myeloma. Haematologica 2004, 89, 628–629
  • [12] Dasgupta RK, Adamson PJ, Davies FE, Rollinson S, Roddam PL, Ashcroft AJ, Dring AM, Fenton JAL, Child JA, Allan JM, Morgan GJ. Polymorphic variation in GSTP1 modulates outcome following therapy for multiple myeloma. Blood. 2003, 102, 2345–2350 http://dx.doi.org/10.1182/blood-2003-02-0444
  • [13] Nelson RL, Davis FG, Persky V et al. Risk of Neoplastic and other diseases among people with heterozygozity for hereditary hemochromatosis. Cancer 1995, 76, 875–879 http://dx.doi.org/10.1002/1097-0142(19950901)76:5<875::AID-CNCR2820760523>3.0.CO;2-Q[Crossref]
  • [14] Haliwell B, Gutterdige JMC. Role of free radicals J. Várkonyi et al. and catalytic metal ions in human disease: An overview. Methods Enzymol. 1990, 186, 1–85 http://dx.doi.org/10.1016/0076-6879(90)86093-B[Crossref]
  • [15] Loeb LA, James EA, Waltersdorph AM et al. Mutagenesis by autooxidation of iron with isolated DNA. Proc. Natl. Acad Sci USA 1988, 85, 3918–3922 http://dx.doi.org/10.1073/pnas.85.11.3918[Crossref]
  • [16] Franchini M, Veneri D. Iron overload and hematological malignancies. The Hematology Journal 2004, 5, 381–38 http://dx.doi.org/10.1038/sj.thj.6200548[Crossref]
  • [17] Várkonyi J, Demeter J, Tordai A, Andrikovics H. The significance of the Hemochromatosis genetic variants in Multiple Myeloma in comparison to that of Myelodysplastic syndrome. Ann Hematol. 2006, 85, 869–871 http://dx.doi.org/10.1007/s00277-006-0178-1[Crossref]
  • [18] Grobois B, Jego P, Attal M, Payen C, Rapp MJ, Fuzibet JG, Maigre M, Bataille R. Familial multiple myeloma: report of fifteen families. Brit J Haematol 1999, 105, 768–770 http://dx.doi.org/10.1046/j.1365-2141.1999.01415.x[Crossref]
  • [19] Grobois B, Gueguen M, Fauchet R, Lebouc H, Guenot A, Lancelin F, Lauvin R, Leblay R, Genetet B. Multiple myeloma in two brothers. Cancer 1986, 58, 2417–2421 http://dx.doi.org/10.1002/1097-0142(19861201)58:11<2417::AID-CNCR2820581111>3.0.CO;2-S[Crossref]
  • [20] Engelhardt M, Ihorst G, Behringer D et al. Incidence of monoclonal B-cell disease in siblings of patients with multiple myeloma. Haematologica 2005, 91, 274–276
  • [21] Capalbo S, Trerotoli P, Ciancio A, Mele G, Serio G, Liso V. Increased risk of lymphoproliferative disorders in relatives of B-CLL patients. Blood 1998; 92(S1): Abstr 4124
  • [22] Jakó J, Szerafin L, Nagy P, Simon A, Kappelmayer J. Familial malignant blood diseases: lessons learned from a 20-year period. Leukemia Lymphoma 2004, 45, 109–111 http://dx.doi.org/10.1080/1042819031000149359[Crossref]
  • [23] Shoenfeld Y, Berliner S, Shaklai M et al. Familial multiple myeloma. A review of thirty-seven families. Postgraduate Medical Journal 1982, 58, 12–16 http://dx.doi.org/10.1136/pgmj.58.675.12[Crossref]
  • [24] Pottern LM, Gart JJ, Nam JM et al. HLA and multiple myeloma among black and white men: evidence of a genetic association. Cancer Epidemiol Biomarkers Prev 1992, 3, 177–182
  • [25] Patel M, Wadee AA, Galpin J, Gavalakis C, Fourie AM, Kuschke RH, Philip V. HLA class I and class II antigens associated with multiple myeloma in southern Africa. Clin. Lab. Haem. 2002, 24, 215–219 http://dx.doi.org/10.1046/j.1365-2257.2002.00448.x[Crossref]
Document Type
Publication order reference
YADDA identifier
bwmeta1.element.-psjd-doi-10_2478_s11536-009-0088-4
Identifiers
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.